10 September 2018: Pulmonary route of administration has proved to be an effective way of systematically delivering biopharmaceuticals and drugs to treat pulmonary and non-pulmonary diseases. It offers several advantages, such as high permeability rate, low enzymatic activity, high blood circulation, quick onset of action, non-invasive delivery of drugs, and large surface area for absorption. Some of the common products used in pulmonary drug delivery are Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), accessories, and nebulizers.
Constant Technological Improvements to Stimulate Preference for Dry Powder Inhalers
Constant Technological Improvements to Stimulate Preference for Dry Powder Inhalers
The MDI product segment represented the leading share in 2016. A large number of prominent companies are involved in extensive R&D activities to launch novel MDIs, which in turn is supplementing the segment growth. High acceptance rate of these devices in emerging economies of Latin America and Asia Pacific is also likely to keep their sales high through 2025. The DPI segment is anticipated to register noteworthy growth in coming years. Rapid technological advancements are expected to play a vital role in the growth of this segment. These inhalers offer merits, such as short administration and preparation time and cost-effectiveness.
Demand for nebulizers is estimated to witness a steady rise over the forecast period (from 2018 to 2025). Nebulizers have a strong adoption rate in homecare and hospitals settings owing to their advantages, such as large dosage administration, greater comfort, and conducive reimbursement scenario. Approval of novel devices will further augment the segment growth. For instance, in December 2017, FDA approved Lonhala Magnair (glycopyrrolate) inhalation solution, a nebulized Long-Acting Muscarinic Antagonist (LAMA) for the treatment of airflow obstruction in patients with COPD.
Market Insights
According to a report by Grand View Research Inc., the global pulmonary drug delivery market is projected to expand at a CAGR of 4.7% from 2018 to 2025. Rising incidence of chronic respiratory diseases is likely to escalate the market growth. Geographically, North America led the global market in 2017. The growth of this region can be attributed to the presence of advanced healthcare infrastructure and growing geriatric population. Some of the key companies in the market are GlaxoSmithKline plc, Boehringer Ingelheim GmbH, 3M Healthcare, AstraZeneca, and Novartis AG.
In-Depth
Research Report On Pulmonary Drug Delivery Devices/Systems Market:
https://www.grandviewresearch.com/industry-analysis/pulmonary-drug-delivery-systems-market
No comments:
Post a Comment